Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?
A partial victory is better than a complete loss. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are experiencing this firsthand.
The two partners had hoped that a U.S. Food and Drug Administration (FDA) advisory committee would recommend COVID-19 vaccine boosters for all Americans ages 16 and up. However, on Friday the panel voted 16-2 against recommending Pfizer-BioNTech boosters for the wide age range.
It wasn't all bad news for Pfizer and BioNTech, though. The FDA advisory committee also voted unanimously to recommend boosters for Americans ages 65 and up as well as for individuals of any age at high risk of severe COVID-19. Could Pfizer stock actually be a smart pick to buy after the partial victory?
Source Fool.com
